Walsh Jeffrey T. 4

What Happened

• Jeffrey T. Walsh, a director of Tenaya Therapeutics, was granted a derivative equity award for 120,000 shares on 2026-05-28. The Form 4 records the award at $0.00 (no cash paid at grant).
• This award was granted under the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan and is reported as a derivative/security-based grant rather than an open-market purchase or sale. Grants like this are commonly part of director compensation and are not an outright purchase of stock.

Key Details

• Transaction date: 2026-05-28; Form 4 filed: 2026-05-29 (timely).
• Award: 120,000 shares recorded at $0.00 (derivative instrument).
• Vesting: The award "will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date," subject to continued service (per footnote).
• Plan: Granted pursuant to Tenaya’s 2021 Equity Incentive Plan (Amended and Restated).
• Shares owned after transaction: not specified in the provided summary of the filing.

Context

• This was an equity award/grant to a director (compensation), not an open-market buy or sale; such grants are routine and do not by themselves indicate a buy/sell signal.
• The filing classifies the grant as a derivative award; the Form 4 shows $0.00 at grant but does not detail exercise/settlement mechanics in the provided footnote beyond the vesting schedule.